行情

NVTA

NVTA

Invitae
NYSE

实时行情|Nasdaq Last Sale

21.64
+0.50
+2.37%
盘后: 21.33 -0.31 -1.43% 19:26 09/20 EDT
开盘
21.11
昨收
21.14
最高
21.77
最低
20.98
成交量
185.76万
成交额
--
52周最高
28.75
52周最低
9.04
市值
20.60亿
市盈率(TTM)
-11.6375
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NVTA 新闻

  • Invitae (NVTA) Dips More Than Broader Markets: What You Should Know
  • Zacks.09/13 21:50
  • Invitae Expands Detect Program to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
  • PR Newswire.09/09 12:30
  • Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
  • Benzinga.09/09 11:35
  • Invitae prices upsized convertible debt offering
  • seekingalpha.09/06 16:18

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

NVTA 简况

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
展开

Webull提供InVitae Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。